Haemonetics Announces CE Mark Certification for the VASCADE MVP® XL Venous Vascular Closure System

BOSTON, Nov. 18, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced CE Mark certification for the VASCADE MVP® XL venous vascular closure system.

VASCADE MVP XL is CE marked under the EU-MDR (European Medical Device Regulation) for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis and time to discharge eligibility compared to conventional closure methods, and enabling same-day discharge in patients who have undergone catheter-based procedures using 10–12F inner diameter (15F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs. Using 58% more collagen and a 9% larger disc than the VASCADE MVP® system, the VASCADE MVP XL system provides a robust closure solution for procedures requiring 10-12F sheaths (up to 15F outer diameter) such as cryoablation or Pulsed Field Ablation (PFA) procedures and Left Atrial Appendage Closure (LAAC).

Sign up for Blog Updates